Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment

Prostate Cancer Clinical Trial

Official title:

Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00061347
• Other study ID #: 030190
• Secondary ID: 03-C-0190
• Status: Completed
• Phase: Phase 1
• First received: May 23, 2003
• Last updated: April 20, 2018
• Start date: May 23, 2003
• Est. completion date: April 19, 2018

Study information

• Verified date: April 19, 2018
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To effectively treat prostate cancer, doctors need an accurate view (via X-rays) of the prostate gland during radiation therapy. To help improve this view, doctors may insert gold markers called fiducials into the prostate by placing hollow gold needles through the rectum and moving a fiducial through each needle. The purpose of the study is to determine whether an MRI scan can help doctors improve their placement of these needles.

Fifteen men will participate in this study. Patients will take the antibiotic levofloxacin for two days prior to the placement of the fiducials, then will have a small enema and another dose of the antibiotic on the morning of the procedure. After being anesthetized, patients will have an antenna-like tube placed into the rectum and have MRI images taken of the area. The doctor will then use these scans to place four fiducials into the prostate. The procedure will require approximately 45 minutes. Patients will be allowed to go home the same day of the procedure, which will be followed by a seven-week course of standard radiation therapy.

Prior to their participation in this study, patients will undergo the following evaluations:

a physical exam, blood work, urine tests, and, if appropriate, an MRI or bone scan.

Description:

Effective image-guided prostate therapies require excellent visualization of the prostate and surrounding anatomy, such that cancerous tissue can be treated while avoiding nearby neural and vascular structures. As such, Magnetic Resonance Imaging is well suited for image-guidance because of its excellent soft tissue contrast, multiplanar capabilities, and the potential to yield spectral/biological tumor mapping. Despite the potential for MRI-guided prostate therapies, there are currently no techniques that allow for precise trans-rectal intraprostatic needle placement in patients.

In this pilot study we seek to validate the accuracy and tolerability of a new system and technique that allows for accurate placement of needles within the prostate based upon MR images. The method is very similar to transrectal ultrasound guided biopsy of the prostate, except that it is applicable within a closed high-field MRI scanner. Four gold fiducial markers will be placed within the prostate under needle guidance in a series of patients with localized prostate cancer before external beam radiotherapy. Fifteen patients will be enrolled onto this study with sample size determined to obtain reasonably precise estimates of mean placement accuracy. The accrual period is expected to be less than a year.

While placement of the fiducial markers has no direct therapeutic benefit for the patient, intraprostatic radiopaque fiducial markers (placed under ultrasound) have shown value in assessing daily setup errors and off-line organ motion during external beam radiation therapy for prostate cancer. Therefore, a secondary objective is to gain experience using these intraprostatic fiducial markers for daily assessment and adjustment of external radiation beam targeting. These markers can also be utilized to aid in CT-MRI fusion and results in better target delineation for treatment planning. In this way, prostate cancer patients who are receiving external-beam radiation therapy may benefit from participation.

Other known NCT identifiers

• NCT00882349

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: April 19, 2018
• Est. primary completion date: May 31, 2004
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 90 Years

Eligibility

• INCLUSION CRITERIA:

• Pathologically confirmed adenocarcinoma of the prostate gland.

• Age greater than or equal to 18 years.

• ECOG performance status of 0 or 1.

• Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed (this does not include routine laboratory tests or imaging studies required to establish eligibility).

EXCLUSION CRITERIA:

Patients with contraindication to transrectal needle placement:

• Bleeding disorder;

• PT/PTT greater than 1.5.times the upper limit of normal;

• Platelets less than 50K;

• Artificial heart valve.

Patients with contraindications to MRI:

• Patients weighing greater than 136 kg (weight limit for scanner table);

• Patients with pacemakers, cerebral aneurysm clips, shrapnel injury, or implanted electronic devices.

• Patients with chronic inflammatory bowel disease.

• Patients with distant metastatic disease.

• Patients with a prior history of pelvic or prostate radiotherapy.

• Cognitively impaired patients who cannot give informed consent.

• Other medical conditions deemed by the PI or associates to make the patient ineligible for protocol investigations, procedures, and high-dose external beam radiotherapy.

Related Conditions & MeSH terms

• Cancer
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Procedure:
• Fiducial marker placement
Placement of fidicual markers under MRI guidance for localization of radiaiton treatment

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center, 9000 Rockville Pike	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, Magener A, Brix G, Delorme S, Zuna I, van Kaick G. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging. 1999 Sep;10(3):260-6. — View Citation

Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology. 1996 Mar;198(3):795-805. — View Citation

Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am. 2000 Jan;38(1):59-85, viii. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To test the hypothesis that MRI guidance allows for accurate fiducial marker placement within the prostate		1, 3, 6, 12, 18, 24, 36, 48, and 60 months
Primary	To determine the toxicity of MR-Guided fiducial marker placement		1, 3, 6, 12, 18, 24, 36, 48, and 60 months
Secondary	To gain preliminary experience using intraprostatic fiducial markers for daily set-up assessment and adjustment of external radiation beam targeting.		completion of study
Secondary	To gain preliminary experience using intraprostatic fiducial markers for image fusion.		completion of study
Secondary	To measure the magnitude of marker migration during the course of radiotherapy.		completion of study
Secondary	To gather data on radiation therapy effects on prostate cancer patients treated at the NCI ROB.		completion of study
Secondary	To gather data on the feasibility, tolerability, and effectiveness of local anesthetic injection along the neurovascular bundle under MRI guidance.		completion of study